Approval · Notice of Compliance 38445 · 2026
XOLAIR: Notice of Compliance 38445
Issued October 9, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38445
- Date
- October 9, 2026
- Company
- Novartis Pharmaceuticals Canada Inc.Montreal, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Labelling updates
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| XOLAIR | Not yet assigned | — |
Medicinal ingredients
- OMALIZUMAB 75 MG per 0.5ML
- OMALIZUMAB 150 MG per ML
- OMALIZUMAB 300 MG per 2ML